Publicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria Biocruces Bizkaia (14)

2022

  1. Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

    Lupus, Vol. 31, Núm. 14, pp. 1770-1776

2021

  1. Anti-phospholipid antibodies do not predict damage in SLE patients in the 21st century-an observational study from the Lupus-Cruces cohort

    Rheumatology (Oxford, England), Vol. 61, Núm. 1, pp. 249-257

  2. Clinical presentation of antiphospholipid syndrome

    Lahita’s Systemic Lupus Erythematosus (Elsevier), pp. 561-574

  3. Pregnancy Control in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome. Part 1: Infertility, Ovarian Preservation and Preconception Assessment. Consensus Document of the Spanish Society of Gynaecology and Obstetrics (SEGO), the Spanish Society of Internal Medicine (SEMI) and the Spanish Society of Rheumatology (SER)

    Reumatologia Clinica, Vol. 17, Núm. 2, pp. 61-66

  4. Pregnancy control in Patients with Systemic Lupus Erythematosus/Antiphospholipid Syndrome. Part 3: Childbirth. Puerperium. Breastfeeding Contraception. Newborn

    Reumatologia Clinica, Vol. 17, Núm. 4, pp. 183-186

  5. Pregnancy control in patients with systemic lupus erythematosus/antiphospholipid syndrome. Part 2: Pregnancy follow-up

    Reumatologia Clinica, Vol. 17, Núm. 3, pp. 125-131

2020

  1. Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: An observational comparative study using routine care data

    PLoS ONE, Vol. 15, Núm. 9 September

  2. Seventy years after Hench’s Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus

    Lupus, Vol. 29, Núm. 10, pp. 1155-1167

2019

  1. Evolution of retinal changes measured by optical coherence tomography in the assessment of hydroxychloroquine ocular safety in patients with systemic lupus erythematosus

    Lupus, Vol. 28, Núm. 4, pp. 555-559

  2. Prolonged remission in SLE is possible by using reduced doses of prednisone: An observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts

    Autoimmunity Reviews, Vol. 18, Núm. 9

  3. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort

    Seminars in Arthritis and Rheumatism, Vol. 49, Núm. 3, pp. 464-468

2017

  1. A Pilot Study of the Usefulness of a Single Olanzapine Plasma Concentration as an Indicator of Early Drug Effect in a Small Sample of First-Episode Psychosis Patients

    Journal of Clinical Psychopharmacology, Vol. 37, Núm. 5, pp. 569-577

2016

  1. SLE: The changing prognosis

    Lupus, Vol. 25, Núm. 12, pp. 1285-1287

2015

  1. Prevalence and significance of persistently positive antiphospholipid antibodies in women with preeclampsia

    Journal of Rheumatology, Vol. 42, Núm. 2, pp. 210-213